News
Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...
Tissue factor pathway inhibitor-2 reduces interstitial collagenase degradation of triple-helical collagen and may be of use in the treatment of atherosclerosis.
14d
Zacks Investment Research on MSNPFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets GoalPfizer PFE announced that the phase III BASIS study evaluating its anti-TFPI inhibitor Hympavzi (marstacimab) for treating patients with hemophilia A or B with inhibitors met its primary endpoint as ...
Topline data were announced from a phase 3 trial evaluating marstacimab for adults and adolescents living with hemophilia A or B with inhibitors.
On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for ...
Protein S, protein C, anti-thrombin, and tissue factor pathway inhibitor (TFPI) restrict clotting and prevent abnormal clot formation.
The FDA has approved Pfizer's Hympavzi, an anti-tissue factor pathway inhibitor for patients age 12 and older with hemophilia A or B.
With Pfizer having recently scored an approval for its tissue factor pathway inhibitor Hympavzi, Centessa Pharmaceuticals has decided that taking its own hemophilia B contender to market is not ...
Concizumab is a tissue factor pathway inhibitor (TFPI) antagonist designed to enhance thrombin production by blocking TFPI—a protein that disrupts blood clotting.
Concizumab for hemophilia: Novo Nordisk’s anti-tissue factor pathway inhibitor therapy is under review for prophylactic use in hemophilia A or B with inhibitors.
Preventive treatment with Pfizer's Hympavzi can reduce bleeding rates in hemophilia A or B patients with inhibitors, new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results